Tapinarof Cream for Adults and Children with Atopic Dermatitis—Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials
Authors:
- Andrew F. AlexisAAAndrew F. Alexis
- Leon KircikLKLeon Kircik
- Raj ChovatiyaRCRaj Chovatiya
- Zakiya P. RiceZRZakiya P. Rice
- Weily SoongWSWeily Soong
- Tina BhutaniTBTina Bhutani
- Philip M. BrownPBPhilip M. Brown
- Stephen C. PiscitelliSPStephen C. Piscitelli
- David S. RubensteinDRDavid S. Rubenstein
- Anna M. TallmanATAnna M. Tallman
- April W. ArmstrongAAApril W. Armstrong
Open Access
- 22 July 2025
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (9) , 2667-2682
Abstract
Introduction Patients with atopic dermatitis (AD) and skin of color have heterogeneous presentations and treatment outcomes, however, they are underrepresented in trials. In the ADORING 1 and 2 phase 3, 8-week randomized trials, tapinarof cream 1% once daily (QD) demonstrated superior efficacy versus vehicle in adults and children down to age 2 years with AD. These analyses evaluate efficacy of tapinarof cream 1% QD stratified by race and Fitzpatrick skin type. Methods The primary endpoint was a Validated Investigator Global Assessment for Atopic Dermatitis™ (vIGA-AD™) score of 0 (clear) or 1 (almost clear) and ≥ 2-grade improvement from baseline at week 8. Secondary endpoints included achieving ≥ 75% improvement in Eczema Area and Severity Index (EASI75). Efficacy evaluations used race categories of Asian, Black or African American, and white, and Fitzpatrick skin types I–III and IV–VI. Results In ADORING 1 and 2, 407 and 406 patients were randomized to tapinarof or vehicle QD (7.3–17.0% Asian; 25.9–35.1% Black/African American 43.0–57.7% white), respectively. Across trials, > 50% had Fitzpatrick skin types IV–VI. Tapinarof demonstrated significant efficacy in adults and children. By race in both trials, the primary endpoint was met by consistently higher proportions treated with tapinarof than vehicle: Asian, 39.5–48.9% versus 3.7–18.5%; Black/African American, 43.1–47.0% versus 17.5–24.1%; white, 49.4–52.1% versus 12.2–14.5%, respectively. Similar, superior responses were reported across Fitzpatrick skin type groups with tapinarof versus vehicle: I–III, 44.8–49.9% versus 13.5–17.7%; IV–VI, 46.8–49.6% versus 15.3–19.5%. EASI75 responses were similarly higher and consistent with tapinarof versus vehicle. Adverse events were mostly mild or moderate, leading to low trial discontinuations (lower with tapinarof than vehicle). Conclusions Tapinarof demonstrated consistent efficacy and was well tolerated versus vehicle in a large, diverse population with AD, regardless of race or Fitzpatrick skin type. Trial registration Clinicaltrials.gov, NCT05014568, NCT05032859. Graphical Abstract avaliable for this article.Keywords
Funding Information
- Dermavant Sciences, an Organon Company
This publication has 36 references indexed in Scilit:
- Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJournal of the American Academy of Dermatology, 2024
- Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis RegistryDermatology and Therapy, 2023
- Diagnosing Atopic Dermatitis in Skin of ColorDermatologic Clinics, 2023
- Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color. Part II: Differences in clinical presentation and disparities in cutaneous disorders in skin of colorJournal of the American Academy of Dermatology, 2022
- One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trialJournal of the American Academy of Dermatology, 2022
- Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitisJournal of the American Academy of Dermatology, 2021
- Genetic ancestry does not explain increased atopic dermatitis susceptibility or worse disease control among African American subjects in 2 large US cohortsJournal of Allergy and Clinical Immunology, 2020
- Racial differences in atopic dermatitisAnnals of Allergy, Asthma & Immunology, 2019
- A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitisJournal of the American Academy of Dermatology, 2019
- The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarizationJournal of Allergy and Clinical Immunology, 2015